Apellis Pharmaceuticals Inc (APLS) - Net Assets
Based on the latest financial reports, Apellis Pharmaceuticals Inc (APLS) has net assets worth $370.15 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.08 Billion) and total liabilities ($705.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check APLS cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $370.15 Million |
| % of Total Assets | 34.42% |
| Annual Growth Rate | 44.35% |
| 5-Year Change | 86.32% |
| 10-Year Change | 1455.61% |
| Growth Volatility | 193.07 |
Apellis Pharmaceuticals Inc - Net Assets Trend (2013–2025)
This chart illustrates how Apellis Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore Apellis Pharmaceuticals Inc assets under control for the complete picture of this company's asset base.
Annual Net Assets for Apellis Pharmaceuticals Inc (2013–2025)
The table below shows the annual net assets of Apellis Pharmaceuticals Inc from 2013 to 2025. For live valuation and market cap data, see Apellis Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $370.15 Million | +61.96% |
| 2024-12-31 | $228.54 Million | +17.49% |
| 2023-12-31 | $194.52 Million | +14.51% |
| 2022-12-31 | $169.87 Million | -14.49% |
| 2021-12-31 | $198.66 Million | -2.88% |
| 2020-12-31 | $204.56 Million | +497.60% |
| 2019-12-31 | $34.23 Million | -78.74% |
| 2018-12-31 | $160.97 Million | +8.08% |
| 2017-12-31 | $148.94 Million | +525.96% |
| 2016-12-31 | $23.79 Million | -31.97% |
| 2015-12-31 | $34.98 Million | +164.48% |
| 2014-12-31 | $13.22 Million | +192.42% |
| 2013-12-31 | $4.52 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Apellis Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 299914951700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.00K | 0.00% |
| Other Comprehensive Income | $-2.10 Million | -0.57% |
| Other Components | $3.39 Billion | 914.56% |
| Total Equity | $370.15 Million | 100.00% |
Apellis Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Apellis Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RTL Group SA
F:RRTL
|
$5.20 Billion |
|
Motilal Oswal Financial Services Limited
NSE:MOTILALOFS
|
$5.20 Billion |
|
Youngor Group Co Ltd
SHG:600177
|
$5.20 Billion |
|
Credito Emiliano S.p.A
F:EAO
|
$5.20 Billion |
|
Inventec Corp
TW:2356
|
$5.19 Billion |
|
Changzhou Xingyu Automotive Lighting Systems Co Ltd
SHG:601799
|
$5.19 Billion |
|
Loar Holdings Inc.
NYSE:LOAR
|
$5.18 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
$5.18 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Apellis Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 228,539,000 to 370,147,000, a change of 141,608,000 (62.0%).
- Net income of 22,388,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 1,204,999.
- Other factors increased equity by 118,015,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $22.39 Million | +6.05% |
| Other Comprehensive Income | $1.20 Million | +0.33% |
| Other Changes | $118.02 Million | +31.88% |
| Total Change | $- | 61.96% |
Book Value vs Market Value Analysis
This analysis compares Apellis Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.95x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 41.51x to 13.95x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.99 | $40.96 | x |
| 2014-12-31 | $0.73 | $40.96 | x |
| 2015-12-31 | $1.93 | $40.96 | x |
| 2016-12-31 | $1.32 | $40.96 | x |
| 2017-12-31 | $10.74 | $40.96 | x |
| 2018-12-31 | $2.96 | $40.96 | x |
| 2019-12-31 | $0.55 | $40.96 | x |
| 2020-12-31 | $2.72 | $40.96 | x |
| 2021-12-31 | $2.35 | $40.96 | x |
| 2022-12-31 | $1.60 | $40.96 | x |
| 2023-12-31 | $1.64 | $40.96 | x |
| 2024-12-31 | $1.84 | $40.96 | x |
| 2025-12-31 | $2.94 | $40.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Apellis Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.05%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.23%
- • Asset Turnover: 0.93x
- • Equity Multiplier: 2.90x
- Recent ROE (6.05%) is above the historical average (-207.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -87.61% | 0.00% | 0.00x | 1.15x | $-4.41 Million |
| 2014 | -81.57% | 0.00% | 0.00x | 1.08x | $-12.11 Million |
| 2015 | -132.99% | 0.00% | 0.00x | 1.09x | $-50.01 Million |
| 2016 | -114.00% | 0.00% | 0.00x | 1.15x | $-29.50 Million |
| 2017 | -34.25% | 0.00% | 0.00x | 1.22x | $-65.90 Million |
| 2018 | -79.21% | 0.00% | 0.00x | 1.26x | $-143.60 Million |
| 2019 | -890.18% | 0.00% | 0.00x | 11.37x | $-308.13 Million |
| 2020 | -168.60% | -137.59% | 0.26x | 4.70x | $-365.33 Million |
| 2021 | -375.69% | -1121.27% | 0.08x | 4.44x | $-766.22 Million |
| 2022 | -383.92% | -864.70% | 0.10x | 4.48x | $-669.16 Million |
| 2023 | -271.76% | -133.29% | 0.50x | 4.05x | $-548.08 Million |
| 2024 | -86.58% | -25.32% | 0.88x | 3.87x | $-220.73 Million |
| 2025 | 6.05% | 2.23% | 0.93x | 2.90x | $-14.63 Million |
Industry Comparison
This section compares Apellis Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Apellis Pharmaceuticals Inc (APLS) | $370.15 Million | -87.61% | 1.90x | $5.20 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy… Read more